NCT02663518 2024-05-10A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid TumorsPfizerPhase 1 Terminated249 enrolled 43 charts
NCT03878524 2024-03-04Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialOHSU Knight Cancer InstitutePhase 1 Terminated2 enrolled
NCT03588936 2021-10-11Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic TransplantMedical College of WisconsinPhase 1 Terminated2 enrolled
NCT02599649 2020-01-14Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)M.D. Anderson Cancer CenterPhase 2 Terminated10 enrolled 8 charts
NCT02421354 2019-05-15Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera MyelofibrosisM.D. Anderson Cancer CenterPhase 2 Terminated8 enrolled 7 charts